Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.

Molecular therapy : the journal of the American Society of Gene Therapy - 2 Feb 2022

Lee Young-Ho, Lee Hyeong Ji, Kim Hyung Cheol, Lee Yujean, Nam Su Kyung, Hupperetz Cedric, Ma Jennifer S Y, Wang Xinxin, Singer Oded, Kim Won Seog, Kim Seok Jin, Koh Youngil, Jung Inkyung, Kim Chan Hyuk

Abstract excerpt

CD19-targeting chimeric antigen receptor (CAR) T cells have become an important therapeutic option for patients with relapsed and refractory B cell malignancies. However, a significant portion of patients still do not benefit from the therapy owing to various resistance mechanisms, including high expression of multiple inhibitory immune checkpoint receptors. Here, we report a lentiviral two-in-one CAR T approach...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD19
Share to Down-Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Lymphoma, Large B-Cell, Diffuse

Share to Phenotype

Share to Programmed Cell Death 1 Receptor

Share to Receptors, Immunologic

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 34628052
DOI: 10.1016/j.ymthe.2021.10.004
PMCID: PMC8821960

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.PMID 34628052Read ↗

Simultaneous, cell-intrinsic downregulation of PD-1 and TIGIT enhances the effector function of CD19-targeting CAR T cells and promotes an early-memory phenotypeSemantic proximity Read ↗

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read ↗

From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapySemantic proximity Read ↗

Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin LymphomaSemantic proximity Read ↗

PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challengesSemantic proximity Read ↗

Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.Semantic proximity Read ↗

Chimeric antigen receptor-modified T cells strike backSemantic proximity Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

Engineering better chimeric antigen receptor T cellsSemantic proximity Read ↗

Sequential single cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin’s lymphomaSemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

CAR-T design: Elements and their synergistic functionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.